Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Zerion Pharma

Mindre end 1K følgere
Coverage
Disclaimer
Henrik Ekman
Henrik Ekman

Equity Research Analyst

Alle
Analyse
Selskabspræsentationer
ViserAlle indholdstyper
Zerion Pharma: A disruptive solution for poor drug solubility
Analytikerkommentar16.3.2023, 16.26 af
Claus Thestrup

Zerion Pharma: A disruptive solution for poor drug solubility

Zerion Pharma's CEO Ole Wiborg dived into the potential in the pipeline and the private placement.

Zerion Pharma
Zerion Pharma – A disruptive solution for poor drug solubility
Videopræsentation15.3.2023, 12.00

Zerion Pharma – A disruptive solution for poor drug solubility

Zerion Pharma
Dagens aktienyheder 22/02
Analytikerkommentar22.2.2023, 08.02

Dagens aktienyheder 22/02

Bawat A/S var i går ude med regnskabet for Q4 2022. Zerion Pharma: Private Placement round of € 2-3m.

Bawat Water TechnologiesZerion Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Presentation of Zerion Pharma by CEO Ole Viborg and CFO Jakob Dynes Hansen
Analytikerkommentar21.2.2023, 20.08 af
Claus Thestrup

Presentation of Zerion Pharma by CEO Ole Viborg and CFO Jakob Dynes Hansen

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Zerion Pharma
Zerion Pharma – Regulatory environment and strategic partnerships
Video20.2.2023, 13.30

Zerion Pharma – Regulatory environment and strategic partnerships

Meet Zerion Pharma’s management and regulatory team – CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Zerion Pharma
Zerion Pharma – Company Introduction
Video8.2.2023, 10.00

Zerion Pharma – Company Introduction

Zerion Pharma
Zerion Pharma - Introduction to the company
Analytikerkommentar2.2.2023, 16.52 af
Claus Thestrup

Zerion Pharma - Introduction to the company

Listen to Zerion Pharma’s management team – CEO Ole Wiborg and CFO Jakob Dynnes Hansen introducing the company in relation to a private placement of 2-3 mio. EUR. Zerion Pharma is a non-listed Danish company.

Zerion Pharma
Dagens aktienyheder 01/02 2023
Analytikerkommentar1.2.2023, 08.21

Dagens aktienyheder 01/02 2023

Agillic annoncerede i går eftermiddag svenske AJ Produkter som ny kunde. Ringkjøbing Landbobank har som en af de første danske banker udsendt årsregnskab for 2022. Erria A/S er her til morgen ude med nyheden om, at selskabets CEO Henrik N. Andersen er udpeget som General Director for Erria Container Services. Mød Zerion Pharma’s management team.

AgillicRingkjøbing LandbobankErriaZerion Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.